GEN Exclusives

More »

The Lists

More »
Apr 8, 2013

Top 20 Best-Selling Drugs Approved and Launched During 2012

What new medicines are shaking things up?

Top 20 Best-Selling Drugs Approved and Launched During 2012

These new drugs have made the most money since their market debut last year. [© Saharrr - Fotolia.com]

  • #10. Linzess™ (linaclotide)

    2012 sales: $19.2 million9

    Marketer(s): Ironwood Pharmaceuticals and Forest Laboratories

    Indication(s): Irritable bowel syndrome with constipation and chronic idiopathic constipation in adults

    Date of FDA approval: August 30, 2012

  • #9. Erivedge® (vismodegib)

    2012 sales: $30.9 million (CHF 29 million)10

    Marketer(s): Roche (Genentech)

    Indication(s): Advanced basal cell carcinoma in adults who cannot have surgery or radiation therapy

    Date of FDA approval: January 30, 2012

  • #8. Zaltrap® (ziv-aflibercept)

    2012 sales: $32.3 million (€25 million)11

    Marketer(s): Sanofi and Regeneron

    Indication(s): Metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI) chemotherapy regimen

    Date of FDA approval: August 3, 2012

    Date of European Commission approval: February 5, 2013

  • #7. Stivarga™ (regorafenib)

    2012 sales: $41.4 million (€32 million)12,13

    Marketer(s): Bayer HealthCare and Onyx Pharmaceuticals

    Indication(s): Metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy

    Date of FDA approval: September 27, 2012

  • #6. Stribild™ (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)

    2012 sales: $57.536 million14

    Marketer(s): Gilead Sciences

    Indication(s): HIV-1 infection in adults who are antiretroviral treatment-naïve

    Date of FDA approval: August 27, 2012

  • #5. Perjeta® (pertuzumab)

    2012 sales: $59.7 million (CHF 56 million)15

    Marketer(s): Roche (Genentech)

    Indication(s): First-line treatment of HER2-positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, in combination with Herceptin® (trastuzumab) and docetaxel

    Date of FDA approval: June 8, 2012

    Date of European Commission approval: March 5, 2013

  • #4. Kyprolis® (carfilzomib)

    2012 sales: $64 million

    Marketer(s): Onyx Pharmaceuticals

    Indication(s): Multiple myeloma in patients who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy

    Date of FDA approval: July 20, 2012

  • #3. Inlyta® (axitinib)

    2012 sales: $70.1 million16

    Marketer(s): Pfizer

    Indication(s): Advanced renal cell carcinoma after failure of one prior systemic therapy

    Date of FDA approval: January 27, 2012

    Date of European Commission approval: September 4, 2012

  • #2. Xtandi® (enzalutamide)

    2012 sales: $71.5 million

    Marketer(s): Medivation and Astellas Pharma

    Indication(s): Metastatic, castration-resistant prostate cancer in men who have previously received treatment with docetaxel

    Date of FDA approval: August 31, 2012

  • #1. Kalydeco™ (ivacaftor)

    2012 sales: $171.6 million

    Marketer(s): Vertex Pharmaceuticals

    Indication(s): Cystic fibrosis (CF) in patients 6 years old and older who have at least one copy of the G551D mutation in the CF transmembrane conductance regulator (CFTR) gene

    Date of FDA approval: January 31, 2012

    Date of European Commission approval: July 23, 2012


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?